

Hollis-Eden Pharmaceuticals, Inc.

4435 Eastgate Mall, Suite 400

San Diego, CA 92121

Telephone: 858 587 9333

Fax: 858 558 6470

RECEIVED

MAR 27 2003

TECH CENTER 1600/2900



HOLLISEDEN
PHARMACEUTICALS
Serving Humanity

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING BY "FIRST-CLASS MAIL"

Attorney Docket No. : 202.3
Serial No. : 09/820,483
Applicant(s) : Clarence N. Ahlem, et al.
For : Immune Modulation Method Using Steroid Compounds
Attorney : Daryl D. Muenchau, Registration No. 36,616

I hereby certify that the accompanying

Information Disclosure Statement Transmittal; Information Disclosure Statement
(Form 1449-in duplicate) with cited references (14); and Return Prepaid Postcard

are being deposited with the United States Postal Service "First-Class Mail" service on the date indicated below and are addressed to the United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, ATTN: Box DD.

3/14/03
Date of Deposit

Vickie L. Cowan
Vickie L. Cowan



1623

PATENT
Docket No. 202.3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.) Group Art Unit 1623
App. No. : 09/820,483)
Filed : March 29, 2001)
For : IMMUNE MODULATING)
METHOD USING STEROID)
COMPOUNDS)
Examiner : E. Peselev)

RECEIVED
MAR 27 2003
TECH CENTER 1600/2900SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:


Enclosed is form PTO-1449 (in duplicate) listing references that are also enclosed. No fee is required in accordance with 37 C.F.R. § 1.97(b)(1).

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: March 3, 2003By: Daryl D. Muenchau

Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551

 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT - February 24, 2003 (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.3	APPLICATION NO. 09/820,483
	APPLICANT Clarence Ahlem, et al.	
	FILING DATE March 29, 2001	GROUP E. Peselev

RECEIVED
 MAR 27 2003
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	6,117,860	9/12/00	Jennings-White et al.			
	6,127,349	10/3/00	Chasalow			
	6,136,779	10/24/00	Foulkes et al.			
	6,150,336	11/21/00	Deninno et al.			
	6,150,348	11/21/00	Aranco et al.			
	6,153,606	11/28/00	Lardy et al.			
	6,172,088 B1	1/9/01	Simpkins et al.			
	6,180,682 B1	1/30/01	Place			
	6,187,767 B1	2/13/01	Araneo et al.			
	6,194,400 B1	2/27/01	Nefkens et al.			
	6,197,291 B1	3/6/01	Terao et al.			
	6,221,379 B1	4/24/01	Place			
	6,268,376 B1	7/31/01	Gormley et al.			
	6,277,838 B1	8/21/01	Upasani et al.			

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



PATENT
Docket No. 202.3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Clarence N. Ahlem, et al.)	Group Art Unit 1623
App. No.	:	09/820,483)	
Filed	:	March 29, 2001)	
For	:	IMMUNE MODULATING METHOD USING STEROID COMPOUNDS)	
Examiner	:	E. Peselev)	

RECEIVED
MAR 27 2003
TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing references that are also enclosed. No fee is required in accordance with 37 C.F.R. § 1.97(b)(1).

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: March 11, 2003

By: Daryl D. Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT - February 24, 2003 (USE SEVERAL SHEETS IF NECESSARY)		ATTY. DOCKET NO. 202.3	APPLICATION NO. 09/820,483
		APPLICANT Clarence Ahlem, et al.	
		FILING DATE March 29, 2001	GROUP E. Pesele

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		EP 0429187 B1	1/5/94	Europe				
		EP 0934745 A1	8/11/99	Europe				
		EP 1020191 A1	7/19/00	Europe				
		EP 0637203 B1	8/21/02	Europe				
		WO 00/07566	2/17/00	PCT				
		WO 00/21977	4/20/00	PCT				
		WO 00/32176	6/8/00	PCT				
		WO 00/32177	6/8/00	PCT				
		WO 00/32201	6/8/00	PCT				
		WO 00/35472	6/22/00	PCT				

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.3APPLICATION NO.
09/820,483SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT - February 24, 2003APPLICANT
Clarence Ahlem, et al.FILING DATE
March 29, 2001GROUP
E. Peselev

MAR 27 2003

RECEIVED

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 00/36132	6/22/00	PCT				
		WO 00/39148	7/6/00	PCT				
		WO 00/43017	7/27/00	PCT				
		WO 00/54759	9/21/00	PCT				
		WO 00/56757	9/28/00	PCT				

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.